Israel Launches a National MDMA and Psilocybin Trial for PTSD. Here Is What Canadian Practitioners Can Take From It

On Sunday, October 25, 2026, Israel's Ministry of Health announced what Israeli media are describing as the country's first national-scale clinical trial of psychedelic-assisted psychotherapy for post-traumatic stress disorder. According to reporting by Ynet, which first carried the story late on October 24 (UTC) and expanded it on October 25, and by The Times of Israel the same day, the trial will give MDMA and psilocybin, in combination with structured psychotherapy, to "hundreds" of people with chronic, moderate-to-severe PTSD that has not responded adequately to standard first-line treatment.

The announcement is notable less for the compounds than for who is doing the designing. Here the national health ministry is the sponsor, and it has publicly specified how sessions are structured, how many therapists must be present, and how the drugs move from pharmacy to patient. No standalone Ministry press release could be located at the time of writing, so the details below are drawn from the Ynet and Times of Israel reports.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334.

What the Ministry announced

The trial is aimed at adults with chronic PTSD who have already tried first-line treatments. Every candidate is to undergo psychiatric and physical screening before enrolment. The Ministry told Ynet the study is expected to begin "in the coming weeks" and run for about three years.

The context is a sharp rise in PTSD diagnoses since the attacks of October 7, 2023 and the war that followed. Ministry officials, quoted anonymously by Ynet, described current PTSD treatment as "complex and limited" and pointed to growing demand among trauma survivors for unregulated, illegal psychedelic "treatments," which the trial is meant to reduce.

A three-stage protocol, written by a regulator

The most useful part of the announcement for practitioners is the protocol itself, as described by Ynet.

Preparation. Two to three preparatory sessions of roughly 90 minutes each, focused on building the therapeutic alliance, setting expectations, and practising grounding and emotional-regulation skills.

Dosing. Two or three extended drug-assisted sessions of six to eight hours, spaced several weeks apart, held in a licensed clinic with physical monitoring and a physician on site. The Ministry requires two therapists to be present during every dosing session, even though most of the surrounding psychotherapy is delivered by a single therapist.

Integration. Two to four psychotherapy appointments after each dosing session, focused on processing what came up and connecting it to daily life.

Ministry officials were careful about expectations. "It is very important to emphasize that this is not a magic treatment that will make the problem disappear within a few months," one senior official told Ynet, describing the substances as accelerators of psychotherapy rather than treatments in themselves. The same official added: "This is nothing like taking MDMA at a party. There is nothing recreational about it."

Diversion control built into the design

The second practitioner-relevant feature is how the Ministry has handled the drugs themselves. According to both outlets, MDMA and psilocybin will be dispensed by the pharmacy of the medical institution running the trial and handed directly to the licensed therapist on the morning of each treatment. Participants will have no take-home prescriptions, no stored doses, and no access to the substances outside supervised sessions.

Ynet reported that the Ministry drew lessons from Israel's experience with medical cannabis, where patients take the product home over long periods. The trial has been designed so that the only route to the substance is through a clinic, a therapist and a session.

Why this matters for Canadian practitioners

A government trial in one country does not change the regulatory picture in another. MDMA and psilocybin remain controlled substances in Canada, available for therapeutic use only through clinical trials, Health Canada's case-by-case authorization initiated by a physician, or an individual exemption. What the announcement does offer is a national health authority's publicly stated position on three questions Canadian clinicians, colleges and policymakers keep returning to.

Who should be in the room. The two-therapist requirement for dosing sessions, with a physician on site, is another signal that the emerging international standard treats dosing days as a team activity, not a solo one.

How much time it takes. Six-to-eight-hour sessions, preceded by preparation and followed by multiple integration appointments, is a resource-intensive model that bears little resemblance to a 50-minute appointment. Any Canadian clinic or program weighing how it would deliver this work faces the same planning question.

How the substance is controlled. The pharmacy-to-therapist chain of custody is a concrete answer to the diversion concern that often dominates policy debate.

Earlier this fall this blog covered New Zealand's decision to let two psychiatrists prescribe MDMA for treatment-resistant PTSD; Israel's trial is a different mechanism, research rather than prescription, but it is a further example of a national authority building supervised psychedelic-assisted therapy into its mental-health response.

What we do not yet know

Neither report names the lead institution or clinical sites, gives an exact enrolment target, describes the comparator or blinding, or identifies the funding source. Until a protocol is registered or a formal Ministry document is published, practitioners should treat this as an announcement of intent with an unusually detailed delivery model, not as evidence about outcomes.

Preparing for a team-based, protocol-driven field

Whether access in Canada expands through trials, the case-by-case authorization pathway or future regulatory change, the direction of travel internationally is consistent: structured preparation, extended and well-staffed dosing sessions, deliberate integration, and tight control of the substance. Those are skills and systems that can be learned before the regulatory picture settles.

If you are a regulated health professional thinking about where you would fit in that kind of team, ATMA CENA's training pages describe the Advanced Pathways, which include the Psychedelic Therapy Foundations course as part one, and you can book a conversation with a program advisor to talk through which pathway fits your scope of practice.

Sources

1. Israel to test MDMA and psilocybin on hundreds with severe PTSD in first national trial. Ynetnews, 2026.
2. ניסוי לאומי ראשון: החומר מהאקסטזי יינתן לנפגעי פוסט-טראומה. Ynet, 2026.
3. Health Ministry announces national clinical trial of psychedelic substances for treatment of PTSD. The Times of Israel, 2026.
4. משרד הבריאות ישיק ניסוי קליני ראשון מסוגו לטיפול בפוסט-טראומה באמצעות חומרים פסיכדליים. Zman Israel, 2026.